Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.
The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.